AU2009270805B2 - Methods for treating immune-mediated dengue fever infections and antibody-dependent enhancement of dengue fever infections, including dengue hemorrhagic fever and dengue shock syndrome - Google Patents

Methods for treating immune-mediated dengue fever infections and antibody-dependent enhancement of dengue fever infections, including dengue hemorrhagic fever and dengue shock syndrome Download PDF

Info

Publication number
AU2009270805B2
AU2009270805B2 AU2009270805A AU2009270805A AU2009270805B2 AU 2009270805 B2 AU2009270805 B2 AU 2009270805B2 AU 2009270805 A AU2009270805 A AU 2009270805A AU 2009270805 A AU2009270805 A AU 2009270805A AU 2009270805 B2 AU2009270805 B2 AU 2009270805B2
Authority
AU
Australia
Prior art keywords
cys
leu
trp
denv
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009270805A
Other languages
English (en)
Other versions
AU2009270805A1 (en
Inventor
Neil M. Bodie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Trinity Therapeutics Inc
Original Assignee
Trinity Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trinity Therapeutics Inc filed Critical Trinity Therapeutics Inc
Publication of AU2009270805A1 publication Critical patent/AU2009270805A1/en
Application granted granted Critical
Publication of AU2009270805B2 publication Critical patent/AU2009270805B2/en
Priority to AU2017200760A priority Critical patent/AU2017200760A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2009270805A 2008-07-18 2009-07-17 Methods for treating immune-mediated dengue fever infections and antibody-dependent enhancement of dengue fever infections, including dengue hemorrhagic fever and dengue shock syndrome Ceased AU2009270805B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2017200760A AU2017200760A1 (en) 2008-07-18 2017-02-03 Methods for treating immune-mediated dengue fever infections and antibody-dependent enhancement of dengue fever infections, including dengue hemorrhagic fever and dengue shock syndrome

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8194308P 2008-07-18 2008-07-18
US61/081,943 2008-07-18
PCT/US2009/050966 WO2010009380A2 (en) 2008-07-18 2009-07-17 Methods for treating immune-mediated dengue fever infections and antibody-dependent enhancement of dengue fever infections, including dengue hemorrhagic fever and dengue shock syndrome

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017200760A Division AU2017200760A1 (en) 2008-07-18 2017-02-03 Methods for treating immune-mediated dengue fever infections and antibody-dependent enhancement of dengue fever infections, including dengue hemorrhagic fever and dengue shock syndrome

Publications (2)

Publication Number Publication Date
AU2009270805A1 AU2009270805A1 (en) 2010-01-21
AU2009270805B2 true AU2009270805B2 (en) 2016-11-03

Family

ID=41551029

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2009270805A Ceased AU2009270805B2 (en) 2008-07-18 2009-07-17 Methods for treating immune-mediated dengue fever infections and antibody-dependent enhancement of dengue fever infections, including dengue hemorrhagic fever and dengue shock syndrome
AU2017200760A Abandoned AU2017200760A1 (en) 2008-07-18 2017-02-03 Methods for treating immune-mediated dengue fever infections and antibody-dependent enhancement of dengue fever infections, including dengue hemorrhagic fever and dengue shock syndrome

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2017200760A Abandoned AU2017200760A1 (en) 2008-07-18 2017-02-03 Methods for treating immune-mediated dengue fever infections and antibody-dependent enhancement of dengue fever infections, including dengue hemorrhagic fever and dengue shock syndrome

Country Status (13)

Country Link
US (1) US8815813B2 (enExample)
EP (1) EP2320924B1 (enExample)
JP (1) JP5806112B2 (enExample)
CN (1) CN102159231B (enExample)
AU (2) AU2009270805B2 (enExample)
BR (1) BRPI0915968B1 (enExample)
CA (1) CA2731218A1 (enExample)
HR (1) HRP20150620T1 (enExample)
IL (1) IL210717A (enExample)
MX (1) MX2011000647A (enExample)
MY (1) MY160699A (enExample)
SG (1) SG10201500597YA (enExample)
WO (1) WO2010009380A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005086947A2 (en) * 2004-03-10 2005-09-22 Trinity Therapeutics, Inc. Method for inhibiting immune complex formation in a subjetc
WO2010009380A2 (en) 2008-07-18 2010-01-21 Trinity Therapeutics, Inc. Methods for treating immune-mediated dengue fever infections and antibody-dependent enhancement of dengue fever infections, including dengue hemorrhagic fever and dengue shock syndrome
EP3236986A4 (en) * 2014-12-22 2018-10-24 Middle Tennessee State University Methods for treating immune-mediated viral infections
SG11201709573YA (en) * 2015-05-20 2017-12-28 Univ Kagoshima Specific modification of antibody with igg-binding peptide
WO2017189891A1 (en) * 2016-04-27 2017-11-02 Middle Tennessee State University Methods for treating zika viral infections and associated complications
CN109071606A (zh) 2016-06-13 2018-12-21 国立大学法人鹿儿岛大学 利用IgG结合肽的位点特异性放射性同位素标记抗体
CN115804362A (zh) * 2023-02-08 2023-03-17 中国医学科学院医学生物学研究所 一种IFN-α/βR-/-小鼠抗体依赖性增强感染的注射液及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007030475A1 (en) * 2005-09-06 2007-03-15 Trinity Therapeutics, Inc. Methods for treating immune mediated neurological diseases
US20070225231A1 (en) * 2004-03-10 2007-09-27 Bodie Neil M Methods for inhibiting immune complex formation in a subject

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5189014A (en) 1979-12-03 1993-02-23 Cowan Jr Fred M Method of treating cellular Fc receptor mediated hypersensitivity immune disorders
US4383317A (en) 1980-10-30 1983-05-10 Bei Electronics, Inc. Shaft angle encoder having a circuit for synthesizing a skipped track output signal
IT1190891B (it) 1982-06-24 1988-02-24 Anic Spa Metodo per la sintesi in fase solida di polipeptidi retroinvertiti
US5693758A (en) 1987-11-19 1997-12-02 501 Research Corporation Limited Immunoglobulin E competitor
US5932483A (en) 1990-10-16 1999-08-03 Northwestern University Synthetic peptide and its uses
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US6420127B1 (en) 1994-11-18 2002-07-16 Washington University Compounds and pharmaceutical compositions for the treatment and prophylaxis of bacterial infections
JP2000505068A (ja) 1996-03-13 2000-04-25 トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア 補体活性化を阻害する新規ペプチド類
ITMI962628A1 (it) 1996-12-16 1998-06-16 Tecnogen Scpa Composizione farmaceutica
WO2000015214A1 (en) 1998-09-11 2000-03-23 Ilexus Pty Limited Fc RECEPTOR MODULATORS AND USES THEREOF
DE69926009D1 (de) 1998-10-13 2005-08-04 Univ Georgia Res Found Stabilisierte bioaktive peptide und methoden zu ihrer identifikation, synthese und verwendung
US20030190740A1 (en) 1998-10-13 2003-10-09 The University Of Georgia Research Foundation, Inc Stabilized bioactive peptides and methods of identification, synthesis, and use
WO2001045746A2 (en) 1999-12-24 2001-06-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
WO2002038592A2 (de) 2000-11-08 2002-05-16 Affina Immuntechnik Gmbh Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
US6916904B2 (en) 2002-04-24 2005-07-12 Zolaris Biosciences, Llc Inhibition of immune complex formation
JP2005528918A (ja) 2002-06-07 2005-09-29 アースロン・リミテッド 自己免疫疾患用のＦｃγＲＩＩａトランスジェニック動物モデル
AU2002953533A0 (en) 2002-12-24 2003-01-16 Arthron Limited Fc receptor modulating compounds and compositions
EP1789067B8 (en) 2004-08-12 2012-08-15 Helsinn Healthcare S.A. Use of growth hormone secretagogues for stimulating the motility of the gastrointestinal system
EP1960427B1 (en) 2005-12-13 2011-02-23 SuppreMol GmbH Multimeric fc receptor polypeptides
US20120021988A1 (en) 2007-08-14 2012-01-26 Bodie Neil M Methods for treating immune thrombocytopenia
WO2010009380A2 (en) 2008-07-18 2010-01-21 Trinity Therapeutics, Inc. Methods for treating immune-mediated dengue fever infections and antibody-dependent enhancement of dengue fever infections, including dengue hemorrhagic fever and dengue shock syndrome

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070225231A1 (en) * 2004-03-10 2007-09-27 Bodie Neil M Methods for inhibiting immune complex formation in a subject
WO2007030475A1 (en) * 2005-09-06 2007-03-15 Trinity Therapeutics, Inc. Methods for treating immune mediated neurological diseases

Also Published As

Publication number Publication date
EP2320924B1 (en) 2015-03-11
CN102159231B (zh) 2016-06-15
CN102159231A (zh) 2011-08-17
SG10201500597YA (en) 2015-04-29
US20110218157A1 (en) 2011-09-08
JP5806112B2 (ja) 2015-11-10
EP2320924A4 (en) 2012-07-25
AU2009270805A1 (en) 2010-01-21
MX2011000647A (es) 2011-09-29
BRPI0915968B1 (pt) 2021-11-23
EP2320924A1 (en) 2011-05-18
BRPI0915968A2 (pt) 2020-08-18
JP2011528665A (ja) 2011-11-24
MY160699A (en) 2017-03-15
US8815813B2 (en) 2014-08-26
WO2010009380A2 (en) 2010-01-21
HRP20150620T1 (xx) 2015-09-25
IL210717A (en) 2017-07-31
IL210717A0 (en) 2011-03-31
AU2017200760A1 (en) 2017-03-02
CA2731218A1 (en) 2010-01-21
HK1158066A1 (en) 2012-07-13
WO2010009380A9 (en) 2010-04-08

Similar Documents

Publication Publication Date Title
AU2017200760A1 (en) Methods for treating immune-mediated dengue fever infections and antibody-dependent enhancement of dengue fever infections, including dengue hemorrhagic fever and dengue shock syndrome
US10179803B2 (en) Methods for inhibiting immune complex formation in a subject
US20170065670A1 (en) Methods for treating immune mediated neurological diseases
WO2017189891A1 (en) Methods for treating zika viral infections and associated complications
US6916904B2 (en) Inhibition of immune complex formation
US20120021988A1 (en) Methods for treating immune thrombocytopenia
AU2011253771B2 (en) Method for inhibiting immune complex formation in a subject
HK1158066B (en) A polypeptide for use in treating dengue virus infections

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)